Business news from Ukraine

Business news from Ukraine

“Chervona Zirka” Produced Goods Worth 547 M UAH in 2025

The “Chervona Zirka” Chemical and Pharmaceutical Plant (Kharkiv) produced goods worth 546.883 M UAH in 2025 and sold goods worth 526.744 M UAH.

According to a report published on the company’s website, the cost of goods sold in 2025 amounted to 213.733 million UAH.

The company reported that 96.4% of its output consisted of pharmaceutical products in the form of tablets, capsules, ointments, and tinctures.

Meanwhile, production of perfumes and cosmetics, which accounted for 2.9% of total sales, amounted to 15.121 million UAH.

“Despite the difficult times our country is facing, the company operated as usual in two shifts, with production capacity utilized at 67%. Currently, the company has increased its production and sales volumes compared to the pre-war period. Sales of finished products were primarily conducted on a credit basis, sometimes with payment terms of up to 60 days or on a prepayment basis. Sales volumes for the reporting year amounted to approximately 44 million UAH per month. “The share of the Ukrainian market is up to 2%; there were no exports in 2025,” the company’s report states.

“Chervona Zirka Chemical and Pharmaceutical Plant is a Ukrainian manufacturer of pharmaceuticals, therapeutic cosmetics, and dietary supplements.

According to data from the OpenDataBot system, the company’s net profit for 2024 was 24.063 million UAH, which is 64% more than in 2023.

The company’s ultimate beneficiary is Olena Galkina.

, , , ,

FARMAK PHARMACEUTICAL COMPANY EXPORTS TO EU MEDICATION FOR ARTIFICIAL LUNG VENTILATION OF COVID-19 PATIENTS

PJSC Farmak pharmaceutical company (Kyiv) in April-July exported to the EU propofol, a medication that is used for artificial lung ventilation of patients with coronavirus (COVID-19), worth more than $635,000,
The company told Interfax-Ukraine that due to the shortage of this medication in the EU and its active use for treatment of COVID-19 patients the supplies of the medication were carried out without its registration at the EU’s profile agency, which is a mandatory condition for sale of drugs in Europe.
“Such an exclusion is connected with the crisis, and at the same time it shows the level of confidence in Ukrainian manufacturers and quality of their products,” the company said.

, , , , ,